## DELAWARE WORKERS' COMPENSATION HEALTH CARE PAYMENT SYSTEM (HCPS) PREFERRED DRUG LIST (PDL)

[Adapted from the Delaware Medical Assistance Program (DMAP) Preferred Drug List (PDL), Effective: 01-04-13; Updated 12-13-12]

ANALGESICS, NARCOTIC SHORT								
PREFERRED AGENTS		NON-PREFERRED AGENTS			CRITERION			
butalbital compound/codeine codeine codeine/APAP dihydrocodeine/APAP /caffeine hydrocodone/APA hydrocodone/ibuprofen hydromorphone tablets meperidine	morphine tablets solution, suppositories oxycodone IR oxycodone/APAP oxycodone/ASA oxycodone/ibuprofen pentazocine/APAP pentazocine/naloxone tramadol Zydone	butorphanol nasal carisoprodol/codeine hydromorphone liquid, suppositories levorphanol morphine concentrate oxymorphone	tramadol/APAP Cocet/Plus Ibudone Magnacet Nucynta	Oxecta Opana Reprexain Rybix ODT Zamicet Zolvit	Prior to dispensing non-preferred agents, 2 preferred medications are required documenting either a lack of efficacy or unacceptable side effects. The "Justification For Use Of Non-Preferred Medication" form is available at <a href="http://dowc.ingenix.com/DWC.asp">http://dowc.ingenix.com/DWC.asp</a> .			
	,	ANALGES	ICS, NARCOTIC LO	NG				
PREFERRED AGENTS		NON-PREFERRED AGENTS			CRITERION			
fentanyl transdermal methadone tablets morphine ER tablets <b>Kadian</b> tramadol ER		methadone concentrate soluble tablet, solution morphine ER caps oxymorphone ER	Avinza Butrans Conzip ER Duragesic	Embeda Exalgo Nucynta ER	Prior to dispensing non-preferred agents, 2 preferred medications are required documenting either a lack of efficacy or unacceptable side effects. The "Justification For Use Of Non-Preferred Medication" is available on the DOL web site at <a href="http://dowc.ingenix.com/DWC.asp">http://dowc.ingenix.com/DWC.asp</a> Please note: brand name drugs with a generic available are considered non-preferred unless listed in bold.			
		NEU	ROPATHIC PAIN					
PREFERRED AGENTS		NON-PREFERRED AGENTS			CRITERION			
gabapentin Cymbalta Lidoderm		Gralise Horizant Lyrica	Qutenza Savella		Lidoderm max 2 patches a day.  Prior to dispensing non-preferred agents, 2 preferred medications are required documenting either a lack of efficacy or unacceptable side effects. The "Justification For Use Of Non-Preferred Medication" form is available at <a href="http://dowc.ingenix.com/DWC.asp">http://dowc.ingenix.com/DWC.asp</a> .			

		NSAIDs		
PREFERRED AGENTS	NON-PRE	FERRED AGENTS		CRITERION
etodolac	diclofenac	meloxicam	Celebrex	Prior to dispensing non-preferred agents, 2 preferred
flurbiprofen	diclofenac/misoprostol	suspension	Flector	medications are required documenting either a lack of
ibuprofen	diflunisal	nabumetone	Indocin	efficacy or unacceptable side effects. The "Justification
indomethacin	etodolac SR	naproxen EC	Pennsaid	For Use Of Non-Preferred Medication" form is available at
ketorolac	fenoprofen	naproxen	Sprix	http://dowc.ingenix.com/DWC.asp.
meloxicam tablets	indomethacin	suspension	Vimovo	
naproxen tablets	ketoprofen	oxaprozin	Voltaren gel	
sulindac	meclofenamate	piroxicam	Zipsor	
	mefenamic acid	tolmetin		
	OPHTALMICS,	ALLERGIC CONJU	JNCTIVITIS	
PREFERRED AGENTS	NON-PRE	FERRED AGENTS		CRITERION
cromolyn	azelastine	Alocril	Emadine	Prior to dispensing non-preferred agents, 2 preferred
Alrex	epinastine	Alomide	Lastacaft	medications are required documenting either a lack of
Pataday	Alamast	Bepreve	Patanol	efficacy or unacceptable side effects. The "Justification
				For Use Of Non-Preferred Medication" form is available at
				http://dowc.ingenix.com/DWC.asp.
ox	YCONTIN, OXYCODONE EXTEND	ED RELEASE, ACT	IQ, TRANSMU	COSAL FENTANYL
	Prior writi	ten approval is req	uired,	
	except for an employee on a s	table dose of Oxyc	ontin, as describ	ed below.
				CRITERION
Pursuant to 19 <b>DE ADMIN CODE</b> 1341, Sectio	Use the "Justification For Use Of Non-Preferred			
well as oxycodone extended release; and A	Medication" form, available at			
Non-Preferred Medication List and may on	http://dowc.ingenix.com/DWC.asp to document			
insurance carrier. However, an employee o	continued treatment when an employee was on a stable			
Regulation may continue the use of this me	dose of Oxycontin prior to 9/11/13. If the dose needs to			
- -		-		change, it is no longer considered a "stable dose" and
				reverts to the provisions in Section 4.13.5.